Home›Stock Screener›Gujarat Kidney and Super Speciality

Gujarat Kidney and Super Speciality Share Price Today | Stock Price & Gujarat Kidney and Super Speciality Share Screener

GKSL Healthcare Services
Live Share Price NSE
₹150.55
▼ -1.16 (-0.76%)
2026-11-19 00:00:00
Live Share Price BSE
₹150.45
▼ -1.65 (-1.08%)
2026-11-19 00:00:00

As of November 19, 2026, the live Gujarat Kidney and Super Speciality share price (NSE: GKSL) is ₹150.55 on NSE and ₹150.45 on BSE, down 0.76% from the previous close, with shares trading between ₹148.41 and ₹153.00 in today's trading session, and a 52-week range of ₹99.36–₹194.69. Track Gujarat Kidney and Super Speci marketcap in USD to gauge the company's total market size. Use the Gujarat Kidney and Super Speciality stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Gujarat Kidney and Super Speciality opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹39 and net income of ₹7, with EBITDA of ₹11, an operating margin of 27.0% and a profit margin of 18.0%.

Gujarat Kidney and Super Speciality Market Cap ₹1,260.70 Cr.
GKSL P/E Ratio (TTM) 61.70
Gujarat Kidney and Super Speciality P/B Ratio 4.78
EPS (TTM) ₹2.49
Dividend Yield -
Debt to Equity 0.13
GKSL 52 Week High ₹194.69
Gujarat Kidney and Super Speciality 52 Week Low ₹99.36
Operating Margin 27.00%
Profit Margin 17.95%
GKSL Revenue (TTM) ₹39.00
EBITDA ₹11.00
Net Income ₹7.00
Total Assets ₹298.00
Total Equity ₹255.00

Gujarat Kidney and Super Speciality Share Price Chart

Track the current stock price of Gujarat Kidney and Super Speciality with an interactive chart. Analyse GKSL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Gujarat Kidney and Super Speciality stock quote in one place.

The quote of ₹150.55 sits between the 52-week low of ₹99.36 and the 52-week high of ₹194.69, and the latest session moved -0.76% from the previous close.

Gujarat Kidney and Super Speciality Company Profile - Fundamental Screener

Screen Gujarat Kidney and Super Speciality company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GKSL shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Healthcare Services industry, and it trades under ISIN INE0V0W01025.

Company Details

Classification

Sector Healthcare
Industry Healthcare Services
Sub-Sector Healthcare Services
Segment E

Identifiers and Leadership

ISIN INE0V0W01025

Gujarat Kidney and Super Speciality Balance Sheet Screener

Screen GKSL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹298, up from ₹55 in 2025.

Latest statistics put total assets at ₹298 and shareholder funds at ₹255, with a leverage ratio of 0.13.

Item 2026 2025 2024 2023 2022

Assets

Total Assets 298 55 21 4 4
Current Assets 0 0 0 0 0
Fixed Assets 129 31 14 0 3

Liabilities

Total Liabilities 0 0 0 0 0
Current Liabilities 15 7 6 0 0
Non-Current Liabilities 0 0 0 0 0

Shareholders' Equity

Total Equity 255 27 11 0 0
Share Capital 16 11 0 0 0
Reserves & Surplus 237 15 2 0 0

Gujarat Kidney and Super Speciality Income Statement Screener - Profit & Revenue Analysis

Screen Gujarat Kidney and Super Speciality income statement and profit fundamentals. Analyze GKSL quarterly results. Gujarat Kidney and Super Speciality reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹39 and net profit was ₹7, equal to earnings per unit of ₹0.74, at an operating margin of 27%.

In that period expenses were ₹28, interest cost ₹1 and tax ₹2. The next period listed, 2026-Jun, shows revenue of ₹35 and net profit of ₹5.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept

Revenue and Expenses

Revenue 39 35 31 23 13 15 10 12 9
Expenses 28 26 24 16 8 7 7 7 5

Operating Costs and Margins

EBITDA 11 9 7 7 5 9 3 5 5
Operating Profit % 27.00% 24.00% 21.00% 30.00% 40.00% 57.00% 27.00% 39.00% 52.00%
Depreciation 2 1 2 1 1 1 1 1 1
Interest 1 1 1 1 0 0 0 0 0

Profit and Earnings

Profit Before Tax 9 7 5 5 4 8 2 4 4
Tax 2 2 0 1 1 2 0 1 1
Net Profit 7 5 5 4 3 5 1 3 3
EPS 0.74 0.66 0.81 0.52 0.47 0.85 0.25 0.52 0.65

Gujarat Kidney and Super Speciality Cash Flow Screener - Liquidity Fundamentals

Screen GKSL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹4, and net cash flow was an inflow of ₹11.

Over the same period, investing activities used ₹214 and financing activities provided ₹228.

Item 2026-March 2025-March 2024-March 2023-March

Cash from Operations and Investing

Operating Activities -4 14 1 0
Investing Activities -214 -18 0 0

Financing and Net Cash

Financing Activities 228 6 -1 0
Net Cash Flow 11 2 1 0

Gujarat Kidney and Super Speciality Shareholding Pattern Screener

See Gujarat Kidney and Super Speciality shareholding pattern with promoter, FII, and DII holdings. Check Gujarat Kidney and Super Speciality promoter holding and ownership changes for GKSL on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 71.45%, foreign institutions 6.53%, domestic institutions 0.26% and the public 9.51%, spread across 12,986 shareholders.

The shareholder count was 12,986 in 2026-Sept, compared with 18,301 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Mar

Promoter Holding

Promoter Holding 71.45% 71.45% 71.45% 71.45% 99.10%

Institutional Investors

FII Holding 6.53% 4.88% 4.88% 10.47% 0.00%
DII Holding 0.26% 0.56% 0.56% 1.67% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 9.51% 10.64% 10.64% 11.57% 0.00%
Other Holding 12.26% 12.46% 12.46% 4.84% 0.90%
Shareholder Count 12,986 18,301 18,301 7 7

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Gujarat Kidney and Super Speciality. Gujarat Kidney and Super Speciality dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Gujarat Kidney and Super Speciality.

Gujarat Kidney and Super Speciality Stock Index Membership - Nifty & Sensex

See which indices include Gujarat Kidney and Super Speciality stock. Check GKSL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Gujarat Kidney and Super Speciality is not part of any tracked indices.
Only major market indices are tracked in our system.

Gujarat Kidney and Super Speciality Market Events Screener - Corporate Actions

Get Gujarat Kidney and Super Speciality corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Gujarat Kidney and Super Speciality stock events that may affect GKSL share price, along with derivatives, futures and options activity and sector gainers.

5 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 4, 2026, with a record date of November 4, 2026.

It is followed by Annual General Meeting dated September 28, 2026 and Quarterly Result Announcement dated August 14, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-04 2026-11-04 Quarterly Result Announcement NA -10.13%
2026-09-28 2026-09-28 Annual General Meeting NA 13.39%
2026-08-14 2026-08-14 Quarterly Result Announcement NA 1.20%
2026-05-28 2026-05-28 Quarterly Result Announcement NA -4.88%
2026-02-14 2026-02-14 Quarterly Result Announcement NA 1.61%

Gujarat Kidney and Super Speciality Competitors Screener - Peer Stocks Comparison

Screen GKSL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Apollo Hospitals 125,272 53.50 25,420 15.58% 2,003 61.89
Max Healthcare Institute 100,339 72.60 8,536 18.82% 1,442 76.17
Manipal Health Enterprises 92,333 105.70 10,521 25.80% 917 60.80
Aster DM Quality Care 64,325 114.20 4,769 11.25% 427 57.55
Fortis Healthcare 60,910 57.30 9,179 16.93% 1,064 57.30
Narayana Hrudayalaya 38,984 45.30 7,996 43.43% 811 61.49
Global Health 38,831 63.30 4,509 19.56% 554 64.64
Dr. Lal Path Labs 33,237 56.50 2,864 12.11% 510 54.28
Krishna Institute of Medical Sciences 32,269 163.70 3,931 28.16% 242 66.73
Syngene International 17,533 94.20 3,809 2.56% 317 61.78

Gujarat Kidney and Super Speciality Company Announcements - News & Reports Screener

Screen GKSL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 14, 2026.

The next most recent announcements are dated November 5, 2026 and November 5, 2026.

Date Update Actions
2026-11-14 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-05 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-05 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-05 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-04 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-04 Statement Of Deviation And Variation Submitted For The Quarter Ended On September 30 2026 -
2026-11-04 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-11-04 Board Meeting Outcome for Unaudited Standalone And Consolidated Financial Results For The Quarter Ended September 30 2026 -
2026-10-28 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-23 Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results For The Quarter Ended September 30 2026. -
2026-10-05 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-29 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-28 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-26 Closure of Trading Window -
2026-09-19 Reg. 34 (1) Annual Report. -
2026-09-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-03 AGM To Be Held On 28-09-2026 -
2026-09-03 Reg. 34 (1) Annual Report. -
2026-09-03 Reg. 34 (1) Annual Report. -
2026-09-01 Intimation Of Pre-Advertisement-Notice Of Annual General Meeting Of The Company -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹150.55, within a 52-week range of ₹99.36 to ₹194.69. The P/E ratio is 61.70 and the P/B ratio is 4.78, with earnings per unit of ₹2.49. Market capitalisation stands at ₹1,260.70 Cr. The company operates in the Healthcare sector, in the Healthcare Services industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 5 balance sheet periods, 9 income statement periods, 4 cash flow years and 5 shareholding periods. Information is provided for research and is not investment advice.